These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29454235)

  • 21. Impact of Donor and Recipient
    Shao J; Wang C; Fu P; Chen F; Zhang Y; Wei J
    Ann Pharmacother; 2020 Jul; 54(7):652-661. PubMed ID: 31888346
    [No Abstract]   [Full Text] [Related]  

  • 22. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients.
    Fukudo M; Yano I; Yoshimura A; Masuda S; Uesugi M; Hosohata K; Katsura T; Ogura Y; Oike F; Takada Y; Uemoto S; Inui K
    Pharmacogenet Genomics; 2008 May; 18(5):413-23. PubMed ID: 18408564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of tacrolimus dispositional genetics on acute rejection in the first 2 weeks and estimated glomerular filtration rate in the first 3 months following kidney transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Pharmacogenet Genomics; 2019 Jan; 29(1):9-17. PubMed ID: 30489455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differences in CYP3A genotypes of a liver transplant recipient and the donor liver graft and adjustment of tacrolimus dose.
    Berger FA; Mulder MB; Ten Bosch-Dijksman W; van Schaik RHN; Coenen S; de Winter BCM
    Br J Clin Pharmacol; 2019 Aug; 85(8):1852-1854. PubMed ID: 31190414
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic risk factors for post-transplantation diabetes mellitus in Chinese Han renal allograft recipients treated with tacrolimus.
    Zhang X; Men T; Liu H; Li X; Wang J; Lv J
    Transpl Immunol; 2018 Aug; 49():39-42. PubMed ID: 29665413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of
    Nakamura T; Fukuda M; Matsukane R; Suetsugu K; Harada N; Yoshizumi T; Egashira N; Mori M; Masuda S
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of TLR4 rs1927907 locus polymorphisms on tacrolimus pharmacokinetics in the early stage after liver transplantation.
    Wang Z; Wu S; Chen D; Guo F; Zhong L; Fan J; Peng Z
    Eur J Clin Pharmacol; 2014 Aug; 70(8):925-31. PubMed ID: 24820765
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.
    Rojas LE; Herrero MJ; Bosó V; García-Eliz M; Poveda JL; Librero J; Aliño SF
    Pharmacogenet Genomics; 2013 Oct; 23(10):509-17. PubMed ID: 23873120
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.
    Pinon M; De Nicolò A; Pizzol A; Antonucci M; D'Avolio A; Serpe L; Dell'Olio D; Catalano S; Tandoi F; Romagnoli R; Canaparo R; Calvo PL
    Sci Rep; 2021 Jan; 11(1):443. PubMed ID: 33432012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TLR9 rs352139 Genetic Variant Promotes Tacrolimus Elimination in Chinese Liver Transplant Patients During the Early Posttransplantation Period.
    Ou B; Liu Y; Zhang T; Sun Y; Chen J; Peng Z
    Pharmacotherapy; 2019 Jan; 39(1):67-76. PubMed ID: 30537010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variance in ABCB1 and CYP3A5 does not contribute toward the development of chronic kidney disease after liver transplantation.
    Tapirdamaz Ö; Hesselink DA; el Bouazzaoui S; Azimpour M; Hansen B; van der Laan LJ; Polak WG; Kwekkeboom J; van Schaik RH; van Gelder T; Metselaar HJ
    Pharmacogenet Genomics; 2014 Sep; 24(9):427-35. PubMed ID: 25014506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.
    Uesugi M; Hosokawa M; Shinke H; Hashimoto E; Takahashi T; Kawai T; Matsubara K; Ogawa K; Fujimoto Y; Okamoto S; Kaido T; Uemoto S; Masuda S
    Biol Pharm Bull; 2013; 36(11):1814-21. PubMed ID: 24189425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of tacrolimus and cyclosporin A in CYP3A5 expressing Chinese de novo kidney transplant recipients: a 2-year prospective study.
    Liu LS; Li J; Chen XT; Zhang HX; Fu Q; Wang HY; Xiong YY; Liu S; Liu XM; Li JL; Huang M; Wang CX
    Int J Clin Pract Suppl; 2015 May; (183):43-52. PubMed ID: 26177348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation.
    Yu S; Wu L; Jin J; Yan S; Jiang G; Xie H; Zheng S
    Transplantation; 2006 Jan; 81(1):46-51. PubMed ID: 16421475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of donor and recipient CYP3A5 and ABCB1 genetic polymorphisms on tacrolimus dosage requirements and rejection in Caucasian Spanish liver transplant patients.
    Gómez-Bravo MA; Salcedo M; Fondevila C; Suarez F; Castellote J; Rufian S; Pons JA; Alamo JM; Millán O; Brunet M
    J Clin Pharmacol; 2013 Nov; 53(11):1146-54. PubMed ID: 23900887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
    Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
    Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
    Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.
    Ji E; Choi L; Suh KS; Cho JY; Han N; Oh JM
    Transplantation; 2012 Oct; 94(8):866-72. PubMed ID: 22992768
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.
    Wang L; Li N; Wang MX; Lu SC
    Genet Mol Res; 2015 Apr; 14(2):3191-9. PubMed ID: 25966085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation.
    Elens L; Capron A; Kerckhove VV; Lerut J; Mourad M; Lison D; Wallemacq P; Haufroid V
    Pharmacogenet Genomics; 2007 Oct; 17(10):873-83. PubMed ID: 17885626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.